Antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• HT-29 human colon carcinoma cells exhibit preferential sensitivity to imidazoacridone C-1311.
• Imidazoacridone C-1311 is a potential therapeutic agent investigated for its anti-cancer properties.

Purpose of the Study:

• To elucidate the precise mechanism of cell death induced by imidazoacridone C-1311 in HT-29 colon cancer cells.
• To characterize the cell cycle effects and morphological changes associated with C-1311 treatment.

Main Methods:

• Cell cycle analysis using flow cytometry to assess DNA content and cell progression.
• DNA fragmentation assays, including pulse field electrophoresis and TUNEL assay, to detect DNA damage.
• Biochemical and morphological analyses to identify markers of mitosis and cell death.

Main Results:

• Imidazoacridone C-1311 (at EC(99) dose) caused a delay in S phase progression and subsequent G2 arrest in HT-29 cells.
• Cells exhibited signs of death, including rounding and detachment, 48-96 hours post-treatment.
• Evidence of DNA fragmentation and strand breaks confirmed cell death induction.
• Dying cells displayed mitotic features, such as Cdk1 kinase activation and chromatin condensation, indicating transit through mitosis.

Conclusions:

• Imidazoacridone C-1311 does not induce rapid apoptosis in HT-29 cells.
• The compound triggers a prolonged G2 arrest, followed by entry into mitosis and cell death via mitotic catastrophe.
• This distinct cell death pathway highlights a novel therapeutic mechanism for colon cancer treatment.